Phathom Pharmaceuticals VOQUEZNA Sales Surge 104% in Q1 2026, Company Maintains Profitability Guidance

Key Takeaways

• VOQUEZNA generated $58.3 million in Q1 2026 net revenues, representing a 104% increase compared to the same period last year
• Phathom has filled approximately 1.35 million total VOQUEZNA prescriptions since launch, demonstrating strong market adoption
• Company maintains full-year 2026 guidance and expects to achieve operating profitability beginning in Q3 2026

---

Phathom Pharmaceuticals reported strong first quarter 2026 financial results on April 30, 2026, driven by robust sales of its acid-related disorder treatment VOQUEZNA. The company generated $58.3 million in net revenues during Q1, marking a significant 104% increase compared to the first quarter of 2025.

Strong Prescription Growth Drives Revenue

Since its commercial launch, VOQUEZNA has achieved approximately 1.35 million total prescriptions filled, indicating strong physician and patient adoption of the treatment. This prescription volume reflects growing market acceptance of Phathom’s approach to treating acid-related disorders.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Cost Management and Path to Profitability

Phathom demonstrated disciplined expense management with Q1 operating expenses of $61.8 million and non-GAAP operating expenses of $56.2 million. The company reported net cash usage of approximately $15 million, representing significant year-over-year cost reduction while maintaining commercial momentum.

“Our continued expense discipline and significant year-over-year cost reduction position us well for sustainable growth,” the company indicated in its earnings announcement.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

2026 Outlook Remains Intact

Phathom maintained its full-year 2026 financial guidance, projecting operating profitability to begin in the third quarter of 2026 and continue through the full fiscal year. This timeline reflects the company’s confidence in VOQUEZNA’s commercial trajectory and operational efficiency improvements.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for pharmaceutical intelligence pricing, access, and launch sequencing.

Market Implications

The strong Q1 performance positions Phathom as a growing player in the competitive acid-related disorder treatment market. The combination of revenue growth and cost discipline suggests the company is successfully executing its commercialization strategy while building toward sustainable profitability.

Investors and industry analysts will closely monitor Q2 results to assess whether this growth momentum continues as Phathom approaches its projected profitability milestone.

---

Frequently Asked Questions

What is VOQUEZNA used to treat?

VOQUEZNA is Phathom Pharmaceuticals’ treatment for acid-related disorders, competing in the proton pump inhibitor market segment.

When will Phathom Pharmaceuticals become profitable?

Phathom expects to achieve operating profitability beginning in Q3 2026 and maintain profitability for the full fiscal year 2026.

How many VOQUEZNA prescriptions have been filled?

Approximately 1.35 million total VOQUEZNA prescriptions have been filled since the drug’s commercial launch.

Related coverage

• Eli Lilly raises 2026 revenue guidance on Mounjaro demand
• Sanofi pipeline pdf: Dupixent, Lantus and 2026 catalysts
• Alnylam pipeline update: AMVUTTRA catalysts, outlook and profitability